Ethan R. Lester

Ethan R. Lester

Auto-generated profile, based on publicly available information

Ethan R. Lester

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, 06510, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
HKHajime Kato
Hajime Kato
AAAnenya J Ansh
Anenya J Ansh
ELEthan R Lester
Ethan R Lester
YKYuka Kinoshita
Yuka Kinoshita
NHNaoko Hidaka
Naoko Hidaka
NINobuaki Ito
Nobuaki Ito

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
KZKristin Zimmerman
Kristin Zimmerman
XLXiaochen Liu
Xiaochen Liu
SKSimon von Kroge
Simon von Kroge
PSPaul Stabach
Paul Stabach
ELEthan R. Lester
Ethan R. Lester
DBDemetrios T. Braddock
Demetrios T. Braddock

6 August 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MMMarisa M. Michalchik
Marisa M. Michalchik
TPTony Potchernikov
Tony Potchernikov
ELEthan R. Lester
Ethan R. Lester
DBDemetrios T. Braddock
Demetrios T. Braddock
WCWenxiang Cao
Wenxiang Cao
ECEnrique M. De La Cruz
Enrique M. De La Cruz
Ectonucleotide Pyrophosphatase Phosphodiesterase 1 (ENPP1) is a transmembrane glycoprotein enzyme with an extracellular catalytic domain that hydrolyzes ATP into AMP and pyrophosphate (PPi). The ENPP1 ATPase is the major source of extracellular PPi, a critical physiological regulator of calcium phosphate crystal formation and biomineralization. ENPP1 deficiency lowers systemic PPi levels and induces life-threatening arterial calcifications. Enzyme replacement therapy (ERT) with a soluble ENPP1 biologic restores plasma PPi and eliminates calcification and associated mortality in ongoing clinical trials in patients with ENPP1 deficiency. Despite the significant role of ENPP1 in inhibiting vascular calcification and regulating mammalian biomineralization via extracellular PPi levels, little is known about the molecular mechanism of PPi liberation by ENPP1. Here, we provide a kinetic analysis of the ENPP1 catalytic ATPase cycle. Our analysis shows that ATP cleavage, PPi release, and hydrolysis of the covalent AMP-ENPP1 intermediate are rapid (>1000 sec-1) and that AMP product release is slow and rate-limiting. The steady-state Michaelis constant of ATP substrate (KM,T) is comparable to physiological serum ATP levels of ∼100 nM, rendering ENPP1 activity sensitive to small changes in serum ATP. AMP binds strongly, with an affinity comparable to KM,T, such that ENPP1 is subject to intrinsic regulatory feedback by AMP under physiological concentrations of ∼100 nM. This product inhibition can attenuate ENPP1 during periods of high PPi liberation, maintaining relatively constant plasma PPi levels. The quantitative parameters of the ENPP1 ATPase cycle provided here allow for predictable outcomes of ENPP1 ERT and provide plausible expectations for other PPi-linked calcification disorders.

7 November 2026 in Molecular Therapy
Verified
Journal Article
Open access
DSDominique Sims
Dominique Sims
ELEthan R. Lester
Ethan R. Lester
SLSam G. Lopez
Sam G. Lopez
PSPaul R. Stabach
Paul R. Stabach
DBDemetrios T. Braddock
Demetrios T. Braddock